FGFR3 and neoplasm: In the Mariathasan et al. bladder cancer cohort, SEPHS1 high expression was associated with higher tumor mutational burden (Figure S8B) and distinct mutation patterns, including enriched TP53 and RB1 mutations, while FGFR3 and STAG2 mutations were more common in the low-expression group (Figure S8D).